News

Zacks Investment Research on MSN3d
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...
Nasdaq3d
Kymera Therapeutics Announces $250.8 Million Public Offering of Common Stock and Pre-Funded Warrants - Nasdaq
Kymera Therapeutics, Inc. announced the pricing of its public offering of $250.8 million, consisting of 5,044,500 shares of common stock priced at $44.00 each, along with pre-funded warrants for ...
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
TMCnet4d
Kymera Therapeutics Announces Proposed Public Offering
Kymera intends to use the net proceeds from the offering to continue to advance its pipeline of preclinical and clinical degrader programs that are designed to address large patient populations with ...
Kymera: Sanofi Ends KT-474 Work, Will Advance KT-485
Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.